A new vaccine for an aggressive form of blood cancer has shown promising results in a major clinical trial. The treatment reduced the risk of death by 41% among certain patients with acute myeloid leukemia (AML).
The vaccine is called galinpepimut-S (GPS). It was developed at Memorial Sloan Kettering Cancer Center. Sellas Life Sciences tested the treatment in a Phase 3 clinical trial involving 126 patients.
The results showed a difference in survival between patients receiving the vaccine and those receiving other available treatments. Patients given the vaccine survived for a median of 24 months.
In comparison, patients receiving other treatments had a median survival of 14.7 months. These findings suggest that the treatment could offer additional benefits for selected leukemia patients.
How the New Vaccine Works Against Leukemia
Acute myeloid leukemia is an aggressive cancer that affects the blood and bone marrow. The disease develops when abnormal cells grow rapidly and interfere with normal blood cell production.
Around 20,000 people are diagnosed with AML annually in the United States. Chemotherapy can help patients achieve remission. However, the cancer often returns after treatment.
This makes long-term disease management difficult for many patients. Researchers are therefore exploring treatments that help the immune system fight remaining cancer cells.
Unlike traditional vaccines designed to prevent infections, the new vaccine works differently. It aims to train the immune system to recognize and attack leukemia cells.
The treatment targets cancer cells that may remain after chemotherapy. This approach could help reduce the chances of the disease returning.
Patients Included in the Clinical Trial
The Phase 3 trial included 126 patients with AML. Researchers focused on individuals whose cancer had returned following earlier treatment.
These patients had achieved another remission but were not eligible for bone marrow transplants. The study examined whether GPS could improve their survival outcomes.
The reported results showed a median survival of 24 months among vaccine recipients. This compared with 14.7 months among patients receiving other available treatments.
The reported reduction in the risk of death was 41%. However, the findings apply to the specific patient group included in the trial.
Vaccine Uses Peptides to Activate the Immune System
The GPS vaccine uses peptides to stimulate an immune response against leukemia cells. Peptides are small components of proteins that help the immune system recognize specific targets.
Another feature of the treatment involves its manufacturing process. It can be produced as a ready-made treatment for patients.
This means it does not require a separate formulation for every individual. The approach could make treatment preparation more convenient.
Sellas Life Sciences reported that the vaccine was generally well tolerated during testing. Injection-site reactions were the most commonly reported side effect.
FDA Approval Plans for the New Vaccine
Sellas Life Sciences plans to present detailed clinical trial findings at a future medical conference. The company also intends to seek approval from the US Food and Drug Administration (FDA).
An application is expected during the first half of 2027. However, the treatment still needs to complete the regulatory approval process.
The reported findings represent a potential development in AML treatment. Further evaluation will help determine the vaccine’s role in managing the disease.
In other related news also read Scientists Discover Blood Test That Could Predict Lung Cancer
If approved, the new vaccine could provide another treatment option for selected patients. For now, its availability will depend on the upcoming regulatory review.














